Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis

Yinlong Zhang, Jingyan Wei, Shaoli Liu, Jing Wang, Xuexiang Han, Hao Qin, Jiayan Lang, Keman Cheng, Yiye Li, Yingqiu Qi, Greg J. Anderson, Saraswati Sukumar, Suping Li, Guangjun Nie

Research output: Contribution to journalArticlepeer-review

64 Scopus citations


Extensive evidence has shown that platelets support tumor metastatic progression by inducing epithelial-mesenchymal transition of cancer cells and by shielding circulating tumor cells from immune-mediated elimination. Therefore, blocking platelet function represents a potential new avenue for therapy focused on eliminating metastasis. Here we show that liposomal nanoparticles bearing the tumor-homing pentapeptide CREKA (Cys-Arg-Glu-Lys-Ala) can deliver a platelet inhibitor, ticagrelor, into tumor tissues to specifically inhibit tumor-associated platelets. The drug-loaded nanoparticles (CREKA-Lipo-T) efficiently blocked the platelet-induced acquisition of an invasive phenotype by tumor cells and inhibited platelet-tumor cell interaction in vitro. Intravenously administered CREKA-Lipo-T effectively targeted tumors within 24 h, and inhibited tumor metastasis without overt side effects. Thus, the CREKA-Lipo formulation provides a simple strategy for the efficient delivery of anti-metastatic drugs and shows considerable promise as a platform for novel cancer therapeutics.

Original languageEnglish (US)
Pages (from-to)1062-1071
Number of pages10
Issue number5
StatePublished - 2017


  • Liposomal nanoparticle
  • Metastatic inhibition
  • Tumor associated platelets
  • Tumor metastasis

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)


Dive into the research topics of 'Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis'. Together they form a unique fingerprint.

Cite this